Adicet Bio Inc expected to post a loss of 32 cents a share - Earnings Preview

ADICET Bio

08/08/2025 18:44

Adicet Bio Inc ACET.OQ ACET.O is expected to  show no change in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2025

​LSEG's mean analyst estimate for Adicet Bio Inc is for a loss of 32 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 1.8% in the last three months. ​

Wall Street's median 12-month price target for Adicet Bio Inc is $6.00, about 88.5% above its last closing price of $0.69

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2025
-0.31
-0.30
-0.34
Missed
-11.7
Mar. 31 2025
-0.33
-0.33
-0.31
Beat
6.5
Dec. 31 2024
-0.36
-0.36
-0.32
Beat
11.6​
Sep. 30 2024
-0.35
-0.34
-0.34
Met
0.1
​​Jun. 30 2024
-0.36
-0.36
-0.33
Beat
9.3
Mar. 31 2024
-0.38
-0.39
-0.35
Beat
9.7​
Dec. 31 2023
-0.72
-0.69
-0.69
Met
0.6
Sep. 30 2023
-0.78
-0.74
-1.16
Missed
-57.3

This summary was machine generated August 8 at 17:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)